The revised Bangui Agreement and its annexes 1 to 8, which were formally adopted by the African Intellectual Property Organization on February 28, 2002, maintained the provision of 20-year protection period of patent rights, during which the utilization of product invention patent rights should be made public. Regarding drugs, in order to facilitate regular review by member States, it is stipulated that the final use of drug patents should be made public; It is also stipulated that the use of the product patent right must be approved by the patentee himself, except for the following circumstances. Article 56 of Annex 1 stipulates that according to the involuntary licensing system, when certain patents are of vital importance to a country's economy, public health and national defense, if the people's needs are not met, the relevant ministers of member countries will have the right to issue decrees to use these patents. Therefore, for the sake of public health, when a member state considers it necessary to improve the import channels of a certain drug, the relevant minister may designate an administrative department or agency by decree to produce, import and sell registered patented products according to the principle of involuntary licensing.